Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.42 |
| ▸ | PPARA | Q07869 | 8/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924335 | 1.00 | PPARG (0.42) | PPARGPPARATACR3L3MBTL1S1PR1 | |
| SCHEMBL8222668 | 0.84 | PPARG (0.45) | PPARGPPARAS1PR1S1PR5 | |
| SCHEMBL3917615 | 0.82 | TACR3 (0.43) | TACR3 | |
| SCHEMBL19358569 | 0.82 | GBA1 (0.45) | TACR3 | |
| SCHEMBL14948183 | 0.81 | S1PR1 (0.42) | S1PR1S1PR5 | |
| SCHEMBL3916256 | 0.81 | STS (0.48) | PPARGPPARA | |
| SCHEMBL2934459 | 0.81 | STS (0.48) | PPARGPPARA | |
| SCHEMBL2934462 | 0.81 | STS (0.48) | PPARGPPARA | |
| SCHEMBL3912727 | 0.79 | S1PR5 (0.55) | S1PR1S1PR5 | |
| SCHEMBL8226016 | 0.79 | S1PR5 (0.55) | S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | PPARG 336/4885PPARA 1124/4885TACR3 1504/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | PPARG 336/4885PPARA 1124/4885TACR3 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.